Rhonda Patrick· PhD
ICU admission was reduced from 50% to 2% among Covid-19 patients given oral calcifediol, a major vitamin D metabolite.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
ICU admission was reduced from 50% to 2% among Covid-19 patients given oral calcifediol, a major vitamin D metabolite.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
But if you've already got COVID-19, what they may be saying here is that supplementing not with vitamin D, the product prior to liver metabolism, but in fact, calcifediol 25-hydroxyvitamin D, might be a more efficacious intervention. And that's what they did in this study.